WHO ICTRP trial
A prospective study of atilizumab, bevacizumab and Huaier granules in the…
ChiCTR2100045870 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2100045870 |
|---|---|
| Public title | A prospective study of atilizumab, bevacizumab and Huaier granules in the treatment of unresectable liver cancer |
| Scientific title | A prospective study of atilizumab, bevacizumab and Huaier granules in the treatment of unresectable liver cancer |
| Primary sponsor | Tianjin Medical University General Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | liver cancer |
| Interventions | Experimental group:Atelizumab, bevacizumab combined with Huaier granules;Control group:Atelizumab, bevacizumab |
| Registration date | Apr 25, 2021 |
| Target size | Experimental group:90;Control group:90 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: